北京市中伦（深圳）律师事务所 关于山东威高血液净化制品股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年九月 法律意见书 北京市中伦（深圳）律师事务所 关于山东威高血液净化制品股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：山东威高血液净化制品股份有限公司 根据中国证监会发布的《上市公司股东会规则》（下称"《股东会规则》"）的 有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受山东威高血液 净化制品股份有限公司（下称"公司"）的委托，指派律师出席公司 2025 年第一 次临时股东大会（下称"本次股东大会"），并就本次股东大会的召集和召开程序、 召集人资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意 见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 诚实信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准 确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-024 山东威高血液净化制品股份有限公司 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《关于公司董事离任暨选举职工董事及调整第二届董事会专门委 员会委员的公告》。 表决结果：9 票同意，0 票弃权，0 票反对。 （二）审议通过了《关于选举山东威高血液净化制品股份有限公司董事会薪酬 与考核委员会委员的议案》 第二届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十四次会议于 2025 年 9 月 15 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 9 月 9 日通过通讯方式送达全体董事。本次会议由董事长宋 修山召集并主持，会议应出席董事 9 人，实际出席董事 9 人；公司部分高级管理人 员列席了本次会议。本次会议的召集、召开和表决程序符合《中华人民共和 ...

Group 1 - The core point of the article is the announcement of a significant contract awarded to Shandong Weigao Blood Purification Products Co., Ltd. by Nanning Sixth People's Hospital for medical equipment procurement, with a total bid amount of 1,125,000 [1][2] - Shandong Weigao has participated in 2,055 bidding projects and has made investments in 14 companies, indicating its active role in the industry [1] - The company holds 81 trademark registrations, 393 patents, and 1 copyright, showcasing its strong intellectual property portfolio [1] Group 2 - The procurement was officially announced on September 7, 2025, and is located in the Guangxi Zhuang Autonomous Region [2] - The contract reflects the growing demand for medical equipment in the region, highlighting potential market opportunities for suppliers [2]

Group 1 - The core viewpoint of the news is that Weigao Blood Purification experienced a decline in stock price and trading volume on September 9, with a net financing buy of -1.45 million yuan [1] - On September 9, Weigao Blood Purification had a financing buy amount of 13.34 million yuan, with a total financing balance of 114 million yuan, accounting for 7.40% of its market capitalization [1] - The company specializes in the research, production, and sales of medical products for blood purification, with its main revenue sources being consumables (77.55%), equipment (18.25%), and others (4.20%) [1] Group 2 - As of June 30, the number of shareholders for Weigao Blood Purification was 31,400, a decrease of 47.45% from the previous period, while the average circulating shares per person increased by 90.29% [2] - For the first half of 2025, Weigao Blood Purification reported a revenue of 1.765 billion yuan, representing a year-on-year growth of 8.52%, and a net profit attributable to shareholders of 220 million yuan, up 10.11% year-on-year [2]

Group 1 - The core viewpoint of the news is that 威高血净's stock has experienced fluctuations, with a current price of 40.58 yuan per share and a market capitalization of 16.694 billion yuan [1] - As of September 9, 威高血净's stock has declined by 2.00% year-to-date, with a 4.88% drop over the last five trading days and a 0.95% decline over the last 20 days, while it has increased by 8.56% over the last 60 days [1] - The company has appeared on the龙虎榜 three times this year, with the most recent appearance on September 3, where it recorded a net buy of -18.4591 million yuan [1] Group 2 - 威高血净 operates in the medical and biological industry, specifically in the medical device and medical consumables sectors [2] - For the first half of 2025, 威高血净 reported a revenue of 1.765 billion yuan, representing a year-on-year growth of 8.52%, and a net profit attributable to shareholders of 220 million yuan, which is a 10.11% increase compared to the previous year [2] - The company has a shareholder base of 31,400 as of June 30, with a decrease of 47.45% from the previous period, while the average number of circulating shares per person has increased by 90.29% [2]

证券代码：603014 证券简称：威高血净 公告编号：2025-021 山东威高血液净化制品股份有限公司 薪酬与考核委员会关于公司 2025 年限制性股票 激励计划激励对象名单的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东威高血液净化制品股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第二届董事会第十三次会议，审议通过了《关于公司 2025 年限制性股票 激励计划（草案）及其摘要的议案》（以下简称"本激励计划"）等议案，上述议 案已经第二届董事会薪酬与考核委员会 2025 年第二次会议审议通过。公司已于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）上披露了相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上市 公司信息披露管理办法》等法律、法规及规范性文件的要求，公司对本激励计划 激励对象的姓名和职务在公司内部进行了公示，公司董事会薪酬与考核委员会结 合公示情况对激励对象进行了核查，相关公示情况及核查情况如下： ...

Core Viewpoint - Weigao Blood Products (603014) experienced a decline of 1.55% in stock price, with a trading volume turnover rate of 34.24% and a total transaction amount of 559 million yuan, indicating significant trading activity and potential investor concern [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to its high turnover rate, with a net selling amount of 18.46 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction amount of 212 million yuan, with buying transactions amounting to 96.58 million yuan and selling transactions totaling 115 million yuan, resulting in a net selling of 18.46 million yuan [2]. - The largest buying brokerage was GF Securities, which purchased 31.49 million yuan, while the largest selling brokerage was Huaxin Securities, which sold 34.16 million yuan [2]. Fund Flow - The stock saw a net inflow of 50.76 million yuan from major funds, with a significant inflow of 11.35 million yuan from large orders and 39.41 million yuan from regular orders. Over the past five days, the net inflow of major funds reached 171 million yuan [2]. Financial Performance - According to the semi-annual report released on August 28, the company achieved a revenue of 1.765 billion yuan in the first half of the year, representing a year-on-year growth of 8.52%. The net profit for the same period was 220 million yuan, reflecting a year-on-year increase of 10.11% [2].

Company Overview - Weigao Blood Purification Products Co., Ltd. is located in Weihai, Shandong Province, established on December 27, 2004, and listed on May 19, 2025. The company specializes in the research, production, and sales of medical products for blood purification [1][2]. Financial Performance - For the first half of 2025, Weigao Blood Purification achieved operating revenue of 1.765 billion yuan, representing a year-on-year growth of 8.52%. The net profit attributable to the parent company was 220 million yuan, with a year-on-year increase of 10.11% [2]. Stock Performance - As of September 3, Weigao Blood Purification's stock price increased by 2.04%, reaching 43.53 yuan per share, with a trading volume of 307 million yuan and a turnover rate of 18.75%. The total market capitalization is 17.908 billion yuan [1]. - Year-to-date, the stock price has risen by 5.12%, with a 12.25% increase over the last five trading days, a 9.40% increase over the last 20 days, and an 18.29% increase over the last 60 days [1]. Market Activity - The net inflow of main funds was 28.5053 million yuan, with large orders accounting for 28.07% of total purchases and 17.82% of total sales. The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on September 2, where it recorded a net buy of -16.0277 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Weigao Blood Purification was 31,400, a decrease of 47.45% from the previous period. The average number of circulating shares per person increased by 90.29% to 1,213 shares [2]. Industry Classification - Weigao Blood Purification is classified under the pharmaceutical and biological industry, specifically in the medical device and medical consumables sector. It is part of several concept sectors, including medical devices, mid-cap stocks, and newly listed stocks [2]. Revenue Composition - The company's main business revenue composition is as follows: consumables account for 77.55%, equipment for 18.25%, and other supplementary products for 2.35% [1].

Meeting Overview - The company is holding a temporary shareholders' meeting to discuss various proposals, including the 2025 restricted stock incentive plan [1][2] - The meeting will follow specific procedures to ensure order and efficiency, with provisions for shareholder participation and questioning [1][2] Agenda Items - Proposal 1: Discussion on the company's 2025 interim dividend plan, which aims to enhance shareholder returns [2][3] - Proposal 2: Review of the 2025 restricted stock incentive plan draft and its summary [2][6] - Proposal 3: Examination of the implementation assessment management measures for the 2025 restricted stock incentive plan [2][7] - Proposal 4: Authorization for the board to handle matters related to the 2025 restricted stock incentive plan [2][9] - Proposal 5: Cancellation of the supervisory board and amendments to the company's business scope and articles of association [2][11] - Proposal 6: Development and revision of certain governance systems [2][12] - Proposal 7: Review of candidates for the second board's independent directors and their annual allowances [2][13] Dividend Proposal - The company proposes a mid-year dividend not exceeding 30% of the net profit attributable to shareholders for 2025 [3][4] - The proposed cash dividend is 1.6 yuan per 10 shares, totaling approximately 65.82 million yuan, which represents 29.89% of the net profit for the first half of 2025 [5][6] Restricted Stock Incentive Plan - The company aims to implement a restricted stock incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and core team members [6][7] - The plan's details will be disclosed on August 28, 2025, and it has been approved by the board and supervisory committee [7][9] Governance Changes - The company plans to abolish the supervisory board and amend its articles of association to comply with updated regulations [11] - Several governance systems will be revised to enhance operational standards and compliance with regulatory requirements [12] Independent Director Nomination - The company proposes to nominate Zhang Zhenhua as an independent director, with an annual allowance of 150,000 yuan [13][14] - Zhang Zhenhua meets all qualifications and independence criteria as per relevant regulations [14][15]

山东威高血液净化制品股份有限公司 2025年第一次临时股东大会 会议资料 证券代码:603014 2025年9月 0 资料目录 | 2025年第一次临时股东大会会议须知 2 | | --- | | 2025年第一次临时股东大会议程 3 | | 议案一：关于公司2025年度中期分红的议案 5 | | 议案二：关于公司《2025年限制性股票激励计划（草案）》及其摘要的议案 7 | | 议案三：关于公司《2025年限制性股票激励计划实施考核管理办法》的议案 8 | | 议案四：关于提请公司股东大会授权董事会办理2025年限制性股票激励计划相关事宜的议案.. 9 | | 议案五：关于取消监事会、变更公司经营范围暨修改公司章程的议案 11 | | 议案六：关于制定及修订公司部分治理制度的议案 12 | | 议案七：关于审议第二届董事会独立董事候选人及其年度津贴的议案 13 | 1 2025年第一次临时股东大会会议须知 为维护广大股东的合法权益，确保本次临时股东大会的正常秩序和议事效率， 山东威高血液净化制品股份有限公司（以下简称"公司"）根据《中华人民共和国 公司法》《中华人民共和国证券法》、本公司《公司章程》以及《上 ...